Gómez-Acebo & Pombo has advised Oryzon Genomics, a biotechnology company whose shares are listed on the Continuous Market, in its capital increase through the issuance of more than 12.7 million new ordinary shares at a
Gómez-Acebo & Pombo has advised Oryzon Genomics, a biotechnology company whose shares are listed on the Continuous Market, in its capital increase through the issuance of more than 12.7 million new ordinary shares at a